RU2012105674A - PHARMACEUTICAL COMPOSITION OF ISONIAZID - Google Patents

PHARMACEUTICAL COMPOSITION OF ISONIAZID Download PDF

Info

Publication number
RU2012105674A
RU2012105674A RU2012105674/15A RU2012105674A RU2012105674A RU 2012105674 A RU2012105674 A RU 2012105674A RU 2012105674/15 A RU2012105674/15 A RU 2012105674/15A RU 2012105674 A RU2012105674 A RU 2012105674A RU 2012105674 A RU2012105674 A RU 2012105674A
Authority
RU
Russia
Prior art keywords
isoniazid
rifampicin
pharmaceutical composition
phthalate
sustained release
Prior art date
Application number
RU2012105674/15A
Other languages
Russian (ru)
Inventor
Дипак Динешчандра БХАТТ
Мантан Рохиткумар TРИВЕДИ
Индравадан Амбалал Моди
Бакулеш Мафатлал Хамар
Original Assignee
Кадила Фармасьютикалз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кадила Фармасьютикалз Лтд. filed Critical Кадила Фармасьютикалз Лтд.
Publication of RU2012105674A publication Critical patent/RU2012105674A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

1. Твердая пероральная фармацевтическая композиция, содержащая рифампицин, пиперин и изониазид, где соотношение рифампицина и изониазида находится в диапазоне от 0,3 до 0,9, причем биодоступность рифампицина повышена в присутствии изониазида.2. Твердая пероральная фармацевтическая композиция по п.1, где изониазид находится в форме с замедленным высвобождением.3. Композиция по п.1, где изониазид находится в форме таблетки.4. Композиция по п.3, где изониазид находится в форме таблетки с энтеросолюбильным покрытием.5. Композиция по п.2, где замедленного высвобождения изониазида достигают посредством использования полимеров на основе фталата типа целлюлозы ацетата фталата, гидроксипропилметилцеллюлозы фталата, поливинилацетата фталата и полимеров метакриловой кислоты.1. Solid oral pharmaceutical composition containing rifampicin, piperine and isoniazid, where the ratio of rifampicin and isoniazid is in the range from 0.3 to 0.9, and the bioavailability of rifampicin is increased in the presence of isoniazid. 3. The solid oral pharmaceutical composition of claim 1, wherein the isoniazid is in sustained release form. Composition according to claim 1, wherein the isoniazid is in the form of a tablet. The composition of claim 3, wherein the isoniazid is in the form of an enteric-coated tablet. The composition of claim 2, wherein the sustained release of isoniazid is achieved by using phthalate-based polymers such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, and methacrylic acid polymers.

Claims (5)

1. Твердая пероральная фармацевтическая композиция, содержащая рифампицин, пиперин и изониазид, где соотношение рифампицина и изониазида находится в диапазоне от 0,3 до 0,9, причем биодоступность рифампицина повышена в присутствии изониазида.1. A solid oral pharmaceutical composition containing rifampicin, piperine and isoniazid, where the ratio of rifampicin and isoniazid is in the range from 0.3 to 0.9, and the bioavailability of rifampicin is increased in the presence of isoniazid. 2. Твердая пероральная фармацевтическая композиция по п.1, где изониазид находится в форме с замедленным высвобождением.2. The solid oral pharmaceutical composition according to claim 1, wherein the isoniazid is in sustained release form. 3. Композиция по п.1, где изониазид находится в форме таблетки.3. The composition of claim 1, wherein the isoniazid is in tablet form. 4. Композиция по п.3, где изониазид находится в форме таблетки с энтеросолюбильным покрытием.4. The composition according to claim 3, where isoniazid is in the form of an enteric-coated tablet. 5. Композиция по п.2, где замедленного высвобождения изониазида достигают посредством использования полимеров на основе фталата типа целлюлозы ацетата фталата, гидроксипропилметилцеллюлозы фталата, поливинилацетата фталата и полимеров метакриловой кислоты. 5. The composition according to claim 2, where the sustained release of isoniazid is achieved by using phthalate-based polymers such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate and polymers of methacrylic acid.
RU2012105674/15A 2009-07-31 2010-07-29 PHARMACEUTICAL COMPOSITION OF ISONIAZID RU2012105674A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1765/MUM/2009 2009-07-31
IN1765MU2009 2009-07-31
IN1991/MUM/2009 2009-09-01
IN1991MU2009 2009-09-01
PCT/IB2010/001871 WO2011012987A1 (en) 2009-07-31 2010-07-29 Pharmaceutical composition of isoniazid

Publications (1)

Publication Number Publication Date
RU2012105674A true RU2012105674A (en) 2013-09-10

Family

ID=43528828

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012105674/15A RU2012105674A (en) 2009-07-31 2010-07-29 PHARMACEUTICAL COMPOSITION OF ISONIAZID

Country Status (4)

Country Link
AP (1) AP2012006119A0 (en)
RU (1) RU2012105674A (en)
WO (1) WO2011012987A1 (en)
ZA (1) ZA201200659B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501117A (en) 2013-07-26 2017-01-12 サノフイ Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and method for producing the same
MX2016001155A (en) 2013-07-26 2016-04-29 Sanofi Sa Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation.
EP3773731A1 (en) 2018-04-05 2021-02-17 Cipla Limited Pharmaceutical formulations
CN112438951A (en) * 2019-08-28 2021-03-05 重庆华邦制药有限公司 Method for preparing isoniazid preparation and preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650728B1 (en) * 1993-10-29 2002-02-27 Council of Scientific and Industrial Research Pharmaceutical compositions containing piperine and an antituberculosis or antileprosydrug
AU778389C (en) * 2000-08-09 2006-12-14 Panacea Biotec Limited Novel pharmaceutical compositions of anti-tubercular drugs and process for their preparation

Also Published As

Publication number Publication date
ZA201200659B (en) 2012-10-31
WO2011012987A1 (en) 2011-02-03
AP2012006119A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
JP2019147832A5 (en)
HRP20201480T1 (en) Indolinone derivatives and process for their manufacture
RU2012105674A (en) PHARMACEUTICAL COMPOSITION OF ISONIAZID
JP2012236837A5 (en)
CO6731132A2 (en) Oral Disintegration Tablet
JP2010536766A5 (en)
EA201790661A2 (en) HEPATITIS C VIRUS INHIBITORS
EA201270216A1 (en) PHARMACEUTICAL COMPOSITION
NZ605601A (en) Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
MX2012003982A (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions.
JP2013542218A5 (en)
RU2014127142A (en) PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY FOR HIGH-FUSE HYDROPHOBIC COMPOUND
RU2016149485A (en) SOLID FORMS OF ROMIDEPSIN AND THEIR APPLICATION
EP3056486A3 (en) Process for preparing intermediates for antiviral compounds
JP2013528182A5 (en)
PE20110583A1 (en) RAPID DISGREGATION CAPECITABIN TABLETS
CL2011000296A1 (en) Process for preparing 4-oxo-octahydro-indole-1-carboxylic acid methyl ester and intermediate compounds used.
MX2011008360A (en) Heteroaryl substituted pyridazinone derivatives.
HRP20192275T1 (en) New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
ME00986B (en) New process for synthesiis of ivabradine and addition salts thereof with a pharmaceutically accept able acid
CR20110275A (en) 3-AMINOCICLOPENTANCARBOXAMIDS AS CHEMIOKIN RECEPTOR MODULATORS
NZ714747A (en) Compounds of ‘3-(5-substituted oxy-2,4-dinitro-phenyl)-2-oxo-propionic acid ester’, process and applications thereof
EA201200498A1 (en) A NEW METHOD FOR SYNTHESIS OF IVABRADIN AND ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITIVE SALTS
Lemoine et al. Evaluation of secondary amide replacements in a series of CCR5 antagonists as a means to increase intrinsic membrane permeability. Part 1: Optimization of gem-disubstituted azacycles
ES2527194T3 (en) Tetrahydroquinoline derivatives used as AMPK activators